Stereotactic Radiosurgery (Gamma Knife) Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 6.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Stereotactic Radiosurgery (Gamma Knife) Market Analysis
The stereotactic radiosurgery (gamma knife) market is anticipated to grow with a CAGR of nearly 6.1% during the forecast period.
The COVID-19 pandemic has had ramifications on various surgical procedures. Due to the lockdown restrictions, a delay in diagnosis and treatments was observed in patients with various lifestyle-related and chronic diseases as a result of a reduction in hospital visits, which impacted the studied market. For instance, according to the research study published in August 2020, titled 'Overall Impact of the COVID-19 Pandemic on Interventional Radiology Services: A Canadian Perspective', the COVID-19 pandemic had negatively impacted the interventional radiology services in Canada, especially for elective cases, and as per the study, about 49.3% of the respondents reported that there was an overall decline in interventional radiology services in the country. Thus, this data indicates that surgical procedures declined due to the current pandemic scenario affecting the market. However, with the ongoing vaccinations and decreasing cases of COVID-19, the studied market is expected to bounce back to its full potential over the years.
The major factors that are driving the market growth include the growing prevalence of cancer, brain tumors, and neurological diseases, increasing preference for minimally invasive techniques, and technological advancements. For instance, according to statistics published in February 2022 by Cancer.net, a person's likelihood of developing a brain tumor in their lifetime is less than 1%. Brain tumors account for 85% to 90% of all primary central nervous system (CNS) tumors. Worldwide, an estimated 308,102 people were diagnosed with a primary brain or spinal cord tumor in 2020. Thus, the increasing cases of brain tumor worldwide is expected to increase the demand for stereotactic radiosurgery for its treatment thereby, the market is expected to see a surge over the forecast period.
Moreover, as per the International Agency for Research on Cancer (IARC), published in December 2020, globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men. The IARC stated that the prevalence of cancer rose to 19.3 million cases. With this growing burden, the prevention of cancer is one of the most significant challenges. Therefore, the stereotactic radiosurgery (gamma knife) market is expected to grow over the forecast period.
Moreover, increasing approvals and product launches by key players are expected to boost the market. For example, in May 2022, Elekta launched its next generation stereotactic radiosurgery system, Elekta Esprit, the company's most advanced system offering significantly faster-automated treatment planning for clinicians, more personalized and patient-friendly treatments, and a degree of precision able to protect the mind and the person. Also, the ongoing research and development activities by key players to develop technologically advanced stereotactic radiosurgery (gamma knife) systems are expected to further boost this market revenue throughout the forecast period. However, the high cost and risk associated with gamma knife instruments are hindering market growth.
Stereotactic Radiosurgery (Gamma Knife) Market Trends
This section covers the major market trends shaping the Stereotactic Radiosurgery (Gamma Knife) Market according to our research experts:
Head & Neck Cancer Segment is Expected to Grow With a Healthy CAGR
The head and neck cancer segment is expected to dominate the global stereotactic radiosurgery (gamma knife) market through the forecast period. Gamma knife therapy is used for various cancer indications, including head and neck cancer. Head and neck cancers usually originate in the squamous cells that line the mouth, nose, and throat. The typical symptoms include a persistent sore throat, difficulty swallowing, mouth sores that won't heal, a hoarse voice, and persistent neck swelling from enlarged lymph nodes.
Some of the major trends driving the market segment are the increasing number of cases of target diseases, and the growing aging population that increased the prevalence of chronic diseases. For instance, as per the study published in February 2022, titled "Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy", although the majority of HNC occurs during the fifth and sixth decades of life, approximately 25-40% of the patients are over 70 years old. Moreover, according to the World Health Organization data updated in May 2020, the annual incidence of head and neck cancers worldwide is more than 550,000 cases, with around 300,000 deaths each year. Thus, the increasing prevalence of head and neck cancer globally boosts the market segment.
Additionally, according to the American Society of Clinical Oncology (ASCO), in January 2021, Head and neck cancer accounted for about 4% of all cancers in the United States. In 2020, an estimated 66,630 people (48,740 men and 17,890 women) had developed head and neck cancer. Furthermore, estimated that 14,620 deaths (10,640 men and 3,980 women) from head and neck cancer in 2020. Thus, this huge disease burden will help in the growth of the market. Thus, due to the aforementioned factors, the market segment is expected to see significant growth over the forecast period.
North America is Expected to Dominate the Stereotactic Radiosurgery (Gamma Knife) Market
North America is anticipated to witness a notable growth rate in the global stereotactic radiosurgery (gamma knife) market. Key factors responsible for high growth are increasing disease burden, rising prevalence of cancers & brain tumors, growing awareness amongst healthcare professionals regarding noninvasive treatment alternatives, high adoption of these instruments in surgery centers, and improving healthcare infrastructure in this region.
Cancer is also one of the most prevalent chronic diseases in the country, which is further expected to augment the growth of the market over the years. For instance, according to the GLOBOCAN 2020 report, 101,809 cases of colon cancer, 44,780 cases of rectum cancer, and 26,259 cases of stomach cancer were reported in the United States, which are expected to drive the demand for interventional procedures in the country.
Moreover, the United States has a better healthcare infrastructure than most developed countries. According to the National Cancer Institute (NCI), the national spending on cancer care was USD 156 billion in 2020. Thus, due to the increased funding, the stereotactic market is expected to boost in the region. Moreover, as per the statistics published in February 2022, by Cancer.net, in 2022, an estimated 25,050 adults (14,170 men and 10,880 women) in the United States will be diagnosed with primary cancerous tumors of the brain and spinal cord. As per the same source, about 4,170 children under the age of 15 will also be diagnosed with a brain or CNS tumor in 2022 in the United States. Therefore, with the increasing cases of cancer in the nation, the demand for stereotactic radiosurgery for its treatment is expected to increase, thus, the market is expected to see a surge over the forecast period.
Moreover, the Epidemiology and End Results (SEER) Program estimated that 53,000 new cases of the oral cavity and pharyngeal cancer occurred in the United States in, making up 3% of all new United States cancer cases. The SEER Program also estimated that such cancer cases would account for 10,860 United States deaths in the year, making up 1.8% of all cancer deaths. Thus, the growth in these programs has helped in the overall growth of the market.
Thus, the abovementioned factors are expected to increase market growth.
Stereotactic Radiosurgery (Gamma Knife) Industry Overview
The global stereotactic radiosurgery (gamma knife) market is highly consolidated market. In terms of market share, Elekta AB is currently dominating the market. Some of the market players are Elekta AB, Accuray Incorporated, and Varian Medical Systems. The major market players are focusing on technological advancements to acquire maximum market share.
Stereotactic Radiosurgery (Gamma Knife) Market Leaders
Elekta AB
Accuray Incorporated
Varian Medical Systems
Vision RT Ltd.
Qfix
*Disclaimer: Major Players sorted in no particular order
Stereotactic Radiosurgery (Gamma Knife) Market News
- In May 2022, Elekta launched its next-generation stereotactic radiosurgery system, Elekta Esprit, the company's most advanced system offering significantly faster-automated treatment planning for clinicians, more personalized and patient-friendly treatments, and a degree of precision able to protect the mind and the person.
- In May 2022, a 35-year-old man, who was diagnosed with right-sided vestibular schwannoma, was treated with Stereotactic Radiosurgery (SRS) technique, using a linear accelerator, at Rajiv Gandhi Government General Hospital (RGGGH).
Stereotactic Radiosurgery (Gamma Knife) Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Cancer, Brain Tumors, and Neurological Diseases
4.2.2 Technological Advancements
4.3 Market Restraints
4.3.1 Side Effects and Risks of Treatment
4.3.2 High Cost of Gamma Knife Instruments
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Indication
5.1.1 Head & Neck Cancer
5.1.2 Breast Cancer
5.1.3 Prostate Cancer
5.1.4 Lung Cancer
5.1.5 Spine Cancer
5.1.6 Others
5.2 By End-User
5.2.1 Hospitals
5.2.2 Radiotherapy Centers
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Accuray Incorporated
6.1.2 Elekta AB
6.1.3 Varian Medical Systems, Inc
6.1.4 Vision RT Ltd.
6.1.5 Qfix
6.1.6 Elsan
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Stereotactic Radiosurgery (Gamma Knife) Industry Segmentation
Stereotactic radiosurgery (SRS) is a non-surgical radiation therapy used to treat functional abnormalities and small tumors of the brain. It can deliver precisely targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue. The Stereotactic Radiosurgery (Gamma Knife) Market is segmented By Indication (Head & Neck Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Spine Cancer, and Others), By End User (Hospitals, Radiotherapy Centers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Indication | |
| Head & Neck Cancer | |
| Breast Cancer | |
| Prostate Cancer | |
| Lung Cancer | |
| Spine Cancer | |
| Others |
| By End-User | |
| Hospitals | |
| Radiotherapy Centers | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Stereotactic Radiosurgery (Gamma Knife) Market Research FAQs
What is the current Global Stereotactic Radiosurgery (Gamma Knife) Market size?
The Global Stereotactic Radiosurgery (Gamma Knife) Market is projected to register a CAGR of 6.10% during the forecast period (2024-2029)
Who are the key players in Global Stereotactic Radiosurgery (Gamma Knife) Market?
Elekta AB, Accuray Incorporated , Varian Medical Systems , Vision RT Ltd. and Qfix are the major companies operating in the Global Stereotactic Radiosurgery (Gamma Knife) Market.
Which is the fastest growing region in Global Stereotactic Radiosurgery (Gamma Knife) Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Stereotactic Radiosurgery (Gamma Knife) Market?
In 2024, the North America accounts for the largest market share in Global Stereotactic Radiosurgery (Gamma Knife) Market.
What years does this Global Stereotactic Radiosurgery (Gamma Knife) Market cover?
The report covers the Global Stereotactic Radiosurgery (Gamma Knife) Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Stereotactic Radiosurgery (Gamma Knife) Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Stereotactic Radiosurgery (Gamma Knife) Industry Report
Statistics for the 2024 Global Stereotactic Radiosurgery (Gamma Knife) market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Stereotactic Radiosurgery (Gamma Knife) analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
